Cancer Targeted Technology gets NIH grant to support CTT1403 trial
Cancer Targeted Technology (CTT), a Seattle-based biotech company, has secured a grant of $1.44 million from the US National Institutes of Health (NIH) to support an ongoing clinical trial of a new radiotherapeutic called CTT1403 in prostate cancer. According to the company, the NIH grant has been awarded on the second year of a competitive […]